Extracellular Vesicles from Young Mice Improve Health and Reduce Frailty in Old Mice

Much of cell signaling is carried via extracellular vesicles, membrane-wrapped packages of molecules. Researchers are finding that delivery of extracellular vesicles harvested from stem cells may be a good replacement for first generation stem cell therapies, in which the transplanted cells produce benefits via signaling before dying. Extracellular vesicles are an easier, cheaper approach from a logistical point of view. Here, researchers show that only vesicles generated by stem cells from young mice are capable of producing an impact on frailty in old mice, an indication of the degree to which aging impacts cell signaling and function.

Aging is associated with an increased risk of frailty, disability, comorbidities, institutionalization, falls, fractures, hospitalization, and mortality. Searching for strategies to delay the degenerative changes associated with aging and frailty is interesting. We treated old animals intravenously with small extracellular vesicles (sEVs) derived from adipose mesenchymal stem cells (ADSCs) of young animals, and we found an improvement of several functional parameters usually altered with aging, such as motor coordination, grip strength, fatigue resistance, fur regeneration, and renal function. Frailty index analysis showed that 40% of old control mice were frail, whereas none of the old ADSCs-sEVs treated mice were. Molecular and structural benefits in muscle and kidney accompanied this functional improvement.

ADSCs-sEVs induced pro-regenerative effects and a decrease in oxidative stress, inflammation, and senescence markers. The metabolome of treated mice changed to a youth-like pattern. Very interestingly, the effect of ADSCs-sEVs seems to be finite, as we observed in a more long-term experiment that the effect on the functionality of old mice was lost two months after treatment with ADSC-sEVs. Finally, we gained some insight into the miRNAs contained in sEVs that might be, at least in part, responsible for the effects observed. We propose that young sEVs treatment can be beneficial against frailty and therefore can promote healthy aging.

Link: https://doi.org/10.1101/2021.07.29.454302


Am I the only one impressed with this? Add the right proteins sheathed in fat to the blood and get a younger animal? Isn't this what we are all hoping for?

"Ok, sit right down here and start chatting on your phone. We're going to give you an IV drip, should take about an hour. And when we're done, you'll have a spring in your step before you reach the parking lot, we promise."

So maybe not so dramatic and so quick. But seriously, folk, no comments?

Posted by: Paul at August 9th, 2021 7:45 PM

We have already discussed cellular versicle potential a few months ago. Now we have another study confirming the credibility and now we have more information on the feasibility. Ultimately we could genetically engineer cell lines which will provide the most vesicles and have the best immunological profile. This is a really cool concept . Once developed and mad produced it will be quite affordable. Much simpler and safer than organs and tissues or even cells. With right financing and cell lines some human trials are possible even now or in a few months

Posted by: Cuberat at August 9th, 2021 9:02 PM

So, There are three main types of Extracellular Vesicles : exosomes , microparticles, and apoptotic bodies. I had an infusion of exosomes derived from umbilical cords, now that's young. Did that do any good? I couldn't tell anything, it's been a year.

Posted by: august33 at August 10th, 2021 6:47 PM
Comment Submission

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.